Sangamo Therapeutics (SGMO) Highlights New Preclinical Data Demonstrating Significant Reduction in Tau Expression with Gene Regulation Technology
Tweet Send to a Friend
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) presents data in a podium presentation at the 14th International Conference on Alzheimer's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
